$BMY presented first Phase 3 EXCALIBER-RRMM results for ZENBEXUS with daratumumab on September 25. It will report third-quarter results on October 29, with an i

$BMY presented first Phase 3 EXCALIBER-RRMM results for ZENBEXUS with daratumumab on September 25. It will report third-quarter results on October 29, with an investor call at 8 a.m. ET. The stock is trading inside a broad swing range, with recent rebounds capped near $68.10 and $68.64 and pullback…